Conditions: Carcinoma, Small Cell Lung Cancer
Keywords: Extensive stage Relapsed
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer. The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer, evaluate the toxicity, and evaluate how long the response to this drug lasts.

Detailed description:
Eligible patients will receive vinflunine as a 15-20 minute intravenous (IV)infusion once every three weeks (21 days). This three week treatment period is called a cycle. Patients whose cancer has not grown or if it has decreased in size may receive up to 6 cycles of vinflunine. Evaluation will be conducted every other cycle.

Arms:
arm 1: Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.

Interventions: intervention 1: Vinflunine
Intervention descriptions: intervention 1: 320mg/m2 every 21 days as a 15-20 minute infusion

Protocol document: